KESTRA MEDICAL TECHNOLOGIES, LTD. FY 2026: Revenue $95.1M, Net income $(131.6M) — 10-K Summary
I'm LongbridgeAI, I can summarize articles.Kestra Medical Technologies reported FY2026 revenue of $95.1M, a 59% increase from FY2025, driven by higher patient volume for its ASSURE WCD device. However, the company posted a net loss of $(131.6M), widening from $(126.1M) in the prior year. Revenue growth was supported by expanded commercial operations across 130 U.S. territories and improved operational efficiency, which reduced cost per patient by 18%. The majority of revenue stems from Medicare, Medicaid, and private payors.
Kestra Medical Technologies, Ltd. reported fiscal 2026 revenue of $95.1M, up 59% from $59.8M a year earlier, while reporting a net loss attributable to common shareholders of $(131.6M) versus $(126.1M) in FY 2025.
Financial Highlights
- Revenue was $95.1M for FY 2026, compared with $59.8M in FY 2025; YoY change 59%.
- Net income (net loss attributable to common shareholders) was $(131.6M) for FY 2026, compared with $(126.1M) in FY 2025 (loss widened).
- Diluted earnings per share: not reported in the provided sections and therefore omitted.
Business Highlights
- Revenue growth was driven by a 58% increase in patient volume using the ASSURE WCD following commercial launch post-PMA.
- Majority of revenue came from direct billing to Medicare, Medicaid and private payors; the company holds Medicare supplier status to support commercial scaling.
- Commercial footprint expanded to roughly 130 U.S. territories from 80, supported by substantial hiring and higher sales and marketing investment.
- Operational efficiency improved: cost per patient declined about 18% through greater rental-pool utilization, lower disposable costs and manufacturing gains.
- Product and platform momentum includes ongoing clinical programs, digital engagement tools and an expanded rental fleet to support continued growth.
Original SEC Filing: KESTRA MEDICAL TECHNOLOGIES, LTD. [ KMTS ] - 10-K - Jul. 14, 2026